-
公开(公告)号：US20210317224A1
公开(公告)日：2021-10-14
申请号：US17286437
申请日：2020-08-12
Applicant: I-Mab Biopharma US Limited , ABL Bio Inc.
Inventor： Wenqing Jiang , Lei Fang , Zhengyi Wang , Bingshi Guo , Eunyoung Park , Eunsil Sung , Byungje Sung
Abstract: Provided are bispecific and multi-specific antibodies that target both claudin 18.2 (CLDN18.2) and 4-1BB. These antibodies, in the absence of CLDN18.2-expressing cells, can bind to 4-1BB but are unable to activate 4-1BB signaling. In the presence of CLDN18.2-expressing cells, however, these antibodies can trigger CLDN18.2-dependent 4-1BB signaling, leading to potent immune response to the CLDN18.2-expressing tumor cells.
-
公开(公告)号：US11261259B2
公开(公告)日：2022-03-01
申请号：US17286437
申请日：2020-08-12
Applicant: I-Mab Biopharma US Limited , ABL Bio Inc.
Inventor： Wenqing Jiang , Lei Fang , Zhengyi Wang , Bingshi Guo , Eunyoung Park , Eunsil Sung , Byungje Sung
Abstract: Provided are bispecific and multi-specific antibodies that target both claudin 18.2 (CLDN18.2) and 4-1BB. These antibodies, in the absence of CLDN18.2-expressing cells, can bind to 4-1BB but are unable to activate 4-1BB signaling. In the presence of CLDN18.2-expressing cells, however, these antibodies can trigger CLDN18.2-dependent 4-1BB signaling, leading to potent immune response to the CLDN18.2-expressing tumor cells.
-
公开(公告)号：US12195538B2
公开(公告)日：2025-01-14
申请号：US17298741
申请日：2019-02-15
Applicant: ABL BIO INC. , I-MAB BIOPHARMA US LIMITED
Inventor： Eunyoung Park , Yangsoon Lee , Hyejin Chung , Eunsil Sung , Jiseon Yoo , Minji Park , Yong-Gyu Son , Hyoju Choi , Eunjung Kim , Jaeho Jung , Weon-Kyoo You , Sang Hoon Lee , Lei Fang , Wenqing Jiang
Abstract: The present disclosure provides an anti-PD-L1/anti-4-1BB bispecific antibody capable to effectively block the interactions between PD-L1 and its receptor PD-1 and between 4-1BB and its ligand. The bispecific antibody may have high binding affinity to both of a PD-L1 protein and a 4-1BB protein.
-
公开(公告)号：US20220348675A1
公开(公告)日：2022-11-03
申请号：US17683869
申请日：2022-03-01
Applicant: I-Mab Biopharma US Limited , ABL Bio Inc.
Inventor： Wenqing Jiang , Lei Fang , Zhengyi Wang , Bingshi Guo , Eunyoung Park , Eunsil Sung , Byungje Sung
Abstract: Provided are bispecific and multi-specific antibodies that target both claudin 18.2 (CLDN18.2) and 4-1BB. These antibodies, in the absence of CLDN18.2-expressing cells, can bind to 4-1BB but are unable to activate 4-1BB signaling. In the presence of CLDN18.2-expressing cells, however, these antibodies can trigger CLDN18.2-dependent 4-1BB signaling, leading to potent immune response to the CLDN18.2-expressing tumor cells.
-
公开(公告)号：US10973853B2
公开(公告)日：2021-04-13
申请号：US16483870
申请日：2019-02-11
Applicant: I-Mab Biopharma US Limited
Inventor： Feifei Cui , Lei Fang , Bingshi Guo , Zhengyi Wang , Jingwu Zang
Abstract: The present disclosure provides antibodies and fragments thereof having specificity to a human T cell immunoreceptor with Ig and ITIM domains (TIGIT) protein. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and viral infections are also provided.
-
Patent Agency Ranking
公开(公告)号：US20210054093A1
公开(公告)日：2021-02-25
申请号：US16989702
申请日：2020-08-10
Applicant: I-Mab Biopharma US Limited
Inventor： Zhengyi Wang , Lei Fang , Bingshi Guo , Jingwu Zang
Abstract: The present invention provides novel CD47 antibodies or immunologically active fragments thereof that have low immunogenicity in humans and cause low or no level of red blood cell depletion or hemagglutination, as well as pharmaceutical compositions containing such antibodies that can be used for treatment diseases mediated by CD47 or inhibition of phagocytosis or platelet aggregation.
-
公开(公告)号：US20210015858A1
公开(公告)日：2021-01-21
申请号：US16483870
申请日：2019-02-11
Applicant: I-MAB BIOPHARMA US LIMITED
Inventor： Feifei Cui , Lei Fang , Bingshi Guo , Zhengyi Wang , Jingwu Zang
Abstract: The present disclosure provides antibodies and fragments thereof having specificity to a human T cell immunoreceptor with Ig and ITIM domains (TIGIT) protein. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and viral infections are also provided.
-
公开(公告)号：US20200317789A1
公开(公告)日：2020-10-08
申请号：US16909400
申请日：2020-06-23
Applicant: I-MAB Biopharma US Limited
Inventor： Lei Fang , Zhengyi Wang , Bingshi Guo , Jingwu Zang
IPC: C07K16/28 , A61P31/20 , A61P31/14 , A61P35/00 , A61P35/02 , A61P31/18 , A61P31/22 , A61P31/08 , A61P31/04 , A61P31/06 , A61P31/16 , A61K35/17
Abstract: Provided are anti-PD-L1 antibodies or fragments thereof. The antibodies or fragments thereof specifically bind to the immunoglobulin C domain of the PD-L1 protein. In various example, the antibodies or fragments thereof include a VH CDR1 of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 2, a VH CDR3 of SEQ ID NO: 3, a VL CDR1 of SEQ ID NO: 4, a VL CDR2 of SEQ ID NO: 5, and a VL CDR3 of SEQ ID NO: 6, or variants of each thereof. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and infectious diseases are also provided.
-
公开(公告)号：US11414485B2
公开(公告)日：2022-08-16
申请号：US16687387
申请日：2019-11-18
Applicant: I-MAB Biopharma US Limited
Inventor： Lei Fang , Zhengyi Wang , Bingshi Guo , Jingwu Zang , Wenqing Jiang , Yongqiang Wang
Abstract: The present disclosure provides antibodies that bind Lymphocyte Activation Gene-3 (LAG-3). Also provided are methods of stimulating an immune response, inhibiting growth of tumor cells, and treating an autoimmune, inflammatory, or viral disease.
-
公开(公告)号：US20220112258A1
公开(公告)日：2022-04-14
申请号：US17278157
申请日：2020-07-27
Applicant: I-Mab Biopharma US Limited
Inventor： Feifei Cui , Lei Fang , Yuanyuan Yang , Zhengyi Wang , Bingshi Guo
Abstract: Provided are polypeptides having an antigen-binding unit targeting a tumor antigen and an IL-7 protein or fragment thereof, fused to a Fc fragment. The disclosed polypeptides can be used for treating cancer.
-
-
-
-
-
-
-
-
-
Search Results
22
records
(took 0.036 seconds)
